Homepage

Our Mission

We develop new molecular imaging and theranostic probes for better detection and therapy in patients with cancer. Specializing in emission tomography (PET), radionuclide therapies, and hyperpolarized ¹³C magnetic resonance imaging, our lab members integrate new chemistry, chemical biology, imaging, and clinical methods to create new innovations and methodologies that improve patient care.

---

Research

Our research team focuses on PET/CT and SPECT/CT imaging, radionuclide therapies, and hyperpolarized ¹³C MRI. We develop molecular imaging and theranostic probes, including immunoPET agents for prostate cancer and CD46-targeted therapies for multiple myeloma, as well as tumor-targeted drug delivery and pH imaging to improve prostate cancer detection, all focused on enhancing patient outcomes.

• Advancing Prostate Cancer Theranostics with Novel ImmunoPET Agents
• CD46-targeted Theranostics and Therapy of Multiple Myeloma
• Cerium/Lanthanum-134 as a PET Imaging Theranostic Pair
• Tumor Targeted Drug Delivery using StarPEG Nanocarriers
• pH Imaging Method for Prostate Cancer Detection

Read More About our Research